Compare Nokia Corp (NOK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs BIO-TECHNE Corp — how do they compare? Nokia Corp trades at $11.05 (market cap $56.70B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Nokia Corp is far larger — about 5.1× BIO-TECHNE Corp's market cap, and Nokia Corp pays the higher dividend (1.63%). Which is the better fit depends on your goals.
| NOK | TECH | |
|---|---|---|
Market Cap | $56.70B | $11.16B |
Sector | Technology | Health |
52-Week High | $16.83 | $72.12 |
52-Week Low | $4.05 | $43.31 |
Enterprise Value | $53.51B | $11.24B |
Dividend Yield | 1.63% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.65, up 5.24% on the day, with a bullish analyst consensus price target of $18.00 representing significant upside. Recent earnings show mixed results with a Q1 2026 miss but Q3 and Q4 2025 beats. The company is pivoting toward AI and 5G infrastructure, evidenced by new partnerships and strong revenue growth in these segments. Technical indicators are mixed, with oscillators bullish but moving averages bearish, suggesting near-term consolidation.
The outlook is cautiously optimistic, driven by AI networking demand and strategic deals, but risks include intense competition and execution challenges. Valuation appears stretched with a P/E of 63.22, requiring sustained earnings growth to justify current levels. The stock offers potential for long-term growth if AI initiatives deliver, but near-term volatility is likely.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
